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Quantitation of circulating tumor cells (CTCs) constitutes an emerg-
ing tool for the diagnosis and staging of cancer, assessment of
response to therapy, and evaluation of residual disease after
surgery. Unfortunately, no existing technology has the sensitivity
to measure the low numbers of tumor cells (<1 CTC per ml of whole
blood) that characterize minimal levels of disease. We present a
method, intravital flow cytometry, that noninvasively counts rare
CTCs in vivo as they flow through the peripheral vasculature. The
method involves i.v. injection of a tumor-specific fluorescent ligand
followed by multiphoton fluorescence imaging of superficial blood
vessels to quantitate the flowing CTCs. Studies in mice with
metastatic tumors demonstrate that CTCs can be quantitated
weeks before metastatic disease is detected by other means.
Analysis of whole blood samples from cancer patients further
establishes that human CTCs can be selectively labeled and quan-
titated when present at2 CTCs per ml, opening opportunities for
earlier assessment of metastatic disease.
folate conjugates  in vivo imaging  multiphoton microscopy 
metastasis  cancer diagnosis
The decision to administer chemotherapy after tumor resectionusually depends on an oncologist’s assessment of the presence
of microscopic metastatic disease. Although computed tomogra-
phy, MRI, tissue/sentinel lymph node biopsy, and serum cancer
marker analysis can all detect some level of residual disease, the
presence of circulating tumor cells (CTCs) is reported to correlate
most sensitively with cancer progression and metastasis (1, 2).
Measurement of CTCs, however, remains difficult, with most
methods relying on quantitation of cells expressing epithelial mark-
ers after their isolation from peripheral blood samples (1–6).
Noninvasive imaging of these CTCs in real time as they flow
through the peripheral vasculature could improve detection sensi-
tivity by enabling analysis of significantly larger blood volumes
(potentially the entire blood volume of the patient), but to date such
analyses have proven successful only when cancer cells are labeled
ex vivo before their i.v. injection (7, 8). Although mitochondria-
containing cells and apoptotic cells have been successfully labeled
in vivo for detection in the vasculature (9, 10), no method has yet
been developed for in vivo labeling and quantitation of CTCs. Here
we design and optimize such a method using modified multiphoton
intravital microscopy.
Results
Evaluation and Optimization of the Methods for in Vivo Imaging of
CTCs. Recent estimates suggest that many human carcinomas
overexpress a receptor for the vitamin folic acid (90% of
ovarian and endometrial cancers, 86% of kidney cancers, 78% of
nonsmall cell lung cancers, etc.) (11–17). In contrast, normal
tissues either lack measurable folate receptors (FR) or express
FR at a site that is inaccessible to parenterally administered
drugs. Because FR-expressing cancer masses can be selectively
labeled in vivo by injection of either radioactive or fluorescent
folate conjugates that bind FR with nanomolar affinity (18), we
wondered whether single CTCs might bind sufficient numbers of
folate conjugates to allow their detection in vivo as they pass
through a patient’s peripheral vasculature. To first identify the
optimal method for such detection, we compared the abilities of
nonconfocal, confocal, and multiphoton fluorescence micros-
copy to detect 1,1-dioctadecyl-3, 3,3,3-tetramethylindocarbo-
cyanine perchlorate [DiIC18 (3)]-labeled RBCs in circulation
after their injection into the tail veins of live mice. Analysis of
both signal-to-background ratio and number of cells detected per
minute revealed that multiphoton microscopy was moderately
more sensitive than confocal microscopy, with nonconfocal
microscopy significantly inferior to either method (Table 1 and
Fig. 1a). Because of its superior sensitivity, as well as its
improved tissue penetration and reduced propensity for photo-
damage (19, 20), multiphoton microscopy was selected for all
subsequent studies. Further, to significantly enhance the speed
of data acquisition (a modification essential for capturing CTCs
in rapidly flowing blood vessels), customary two-dimensional
scanning was changed to one-dimensional line scanning along a
transept orthogonal to the flow of blood in the monitored vessel.
This change improved the rate of data acquisition 250-fold (21).
To further increase signal-to-background ratios, a tumor-specific
probe had to be selected that would rapidly clear from circulation
if left uncaptured by CTCs. After multiple comparisons, folate-dye
conjugates were selected over fluorescent antibodies, not only
because labeled antibodies circulate for days before their removal,
thereby causing significant problems with background fluores-
cence, but also because tumor-specific antibodies were found to
promote phagocytic clearance of the CTCs to which they bound,
thereby causing significant underestimation of CTC counts (8), as
shown in the studies below. However, to ensure that folate conju-
gates would clear sufficiently rapidly from circulation to enable
CTC imaging, we injected various folate-dye conjugates i.v. at doses
of 5 nmol per mouse and monitored their depletion kinetics by
intravital time-lapse fluorescence microscopy. As shown in Fig. 1b,
plasma clearance of folate-rhodamine was biphasic, with a rapid
phase characterized by a t12 of3–5 min and comprising 75% of the
clearance in anesthetized mice and a slower phase that we attribute
to serum protein binding. Because these data are similar to those
reported for folate-FITC (22, 23), we assume that folate-dye
conjugates will generally be rapidly excreted if they are not captured
by a FR-expressing cell.
To explore whether cancer cells can be selectively labeled with
folate conjugates in whole blood, whole blood samples from three
healthy donors were spiked with nasopharyngeal cancer cells (KB)
that were first labeled in vitro with the lipophilic dye, DiD (1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine, 4-chloroben-
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zenesulfonate), to allow their tracking. The spiked blood samples
were then treated with 100 nM folate-AlexaFluor 488 and analyzed
by flow cytometry for the presence of both DiD and AlexaFluor
488. Importantly, virtually all DiD-labeled cancer cells were found
to be simultaneously labeled with folate-AlexaFluor 488 (Table 2).
More importantly, no fluorescent cells were detected in any blood
samples lacking cancer cells (data not shown), confirming that the
low level of FR expression on activated monocytes (60,000 per
cell) is too low for detection with intravital flow cytometry.
In Vivo Imaging and Quantitation of CTCs in Murine Cancer Models.
We next introduced L1210A leukemia cells (106) i.v. into BALB/c
mice to mimic the occurrence of natural CTCs. Fifteen minutes
later, folate-rhodamine (5 nmol per mouse) was administered i.v. to
label the CTCs, and after an additional 30 min to allow for clearance
of unbound conjugates, multiphoton intravital microscopy was used
to detect circulating L1210A cells in the vasculature of the ear. One
example of an L1210A cell captured in three consecutive frames
over a period of 1 s is shown in Fig. 1c. To confirm that such cells
were indeed CTCs, we labeled the L1210A cells with DiD before
introducing them into mice and performing the in vivo labeling as
mentioned above (only in this case, labeling was conducted with
folate-FITC to avoid fluorescent crosstalk with DiD). Importantly,
folate-FITC was found to label only DiD-positive cells, as exem-
plified in the representative overlay image of one CTC shown in Fig.
1d. For more quantitative analysis of these CTCs in larger, faster-
flowing vessels, fluorescence scanning was reduced to a single
dimension along a transept perpendicular to the vessel. This
modification allowed an increase in scan rate from 2 to 500 frames
Table 1. Comparison of nonconfocal, confocal, and multiphoton fluorescence scanning
microscopy for in vivo sensing of DiIC18(3)-labeled RBCs
Parameter measured Nonconfocal Confocal Multiphoton
Output power, mW* 1 1 35
Background intensity, a.u. 492–651 47–108 15–47
Signal intensity, a.u. 786–3,895 337–1,588 204–3,895
S/B ratio 1.30–6.98 3.46–21.90 5.51–108.90
S/B mean 2.36  0.96† 9.37  4.37† 22.38  14.52†
Number detected, cells/min‡ 124.0  13.2† 54.8  8.8† 100.0  11.1†
S/B, signal-to-background ratio.
*Output power was measured as the laser power out of objective lens.
†Values are expressed  SD.
‡Number detected represents the number of cells detected by two-photon fluorescence microscopy.
Fig. 1. Optimization of in vivo detection of fluorescent cells in circulation. (a) Dot plot of signal and background intensities of individual fluorescent DiIC18
(3)-labeled RBCs flowing through the vasculature in the ear of a live mouse, as determined by multiphoton (red, n  107), confocal (green, n  55), and
nonconfocal (blue, n 100) microscopy. (b) Kinetics of the clearance of folate-rhodamine from circulation in anesthetized mice. Red arrow marks the injection
point. (c) Overlay image of three consecutive frames spanning 1 s showing an in vivo folate-rhodamine-labeled L1210A cell traveling in a blood vessel. (d)
Specificity of in vivo labeling of L1210A tumor cells with folate-FITC demonstrated by the overlap (yellow) of folate-FITC (green) and DiD (red) fluorescence. (e)
Visualization of digitized signals of fluorescent L1210A cells labeled in vivo with folate-FITC and detected/analyzed by one-dimensional line scanning using
software developed on MATLAB platform. (Scale bars: c and d, 10 m.) Dotted lines outline blood vessel walls identified by transillumination in c and d.











per s. Derived digitized signals obtained by this method were then
processed by using software developed on the MATLAB platform
and found to yield signal to background ratios 8:1 (Fig. 1e).
To study whether CTCs originating from a primary solid
tumor could be quantitated in vivo before metastatic disease was
detectable by microscopic examination of necropsied tissues, a
metastatic tumor model was established by s.c. implanting M109
murine lung cancer cells with moderate FR expression on the
dorsal f lanks of BALB/c mice. By 2 weeks after implantation,
1.4 CTCs per min could be detected in the vasculature of the
ear, whereas by 3 and 4 weeks after implantation, 7 and 18
CTCs per min, respectively, were measured (Fig. 2 a and b).
Indeed, CTC counts increased exponentially with tumor growth.
To determine when metastatic nodules might become visible in
the same animals, the mice were euthanized after in vivo
imaging, and tissue sections (draining lymph nodes, lungs,
kidneys, spleen, liver, bone marrow, etc.) were examined by both
immunohistochemical staining and fluorescence confocal mi-
croscopy. No evidence of metastatic disease was found in any
tissues during the first 4 weeks after tumor implantation, how-
ever, a few micrometastases could be detected in the lungs
(dimensions 50  30  30 m) at week 5. Thus, CTCs were
readily quantitated in circulation weeks before evidence of
metastatic nodules could be found in necropsied tissue sections.
Flow Cytometric Assay of Blood Samples from Ovarian Cancer Pa-
tients. To investigate whether natural CTCs from cancer patients
can be labeled with sufficient folate conjugates to permit their
detection in whole blood, fresh blood samples collected in
heparin from 12 ovarian cancer patients with various pathologies
(patients 1–5, 8, and 10–12: stage III; patient 6: stage I; patient
7: stage II; patient 9: stage IV) were treated with 100 nM
folate-AlexaFluor 488 and then examined by flow cytometry. As
shown in Fig. 2c, except for patients 6 and 7, who had early-stage
cancers, all patients displayed CTC counts significantly greater
than background (6 CTCs per ml). In contrast, similar samples
from three healthy donors were found to contain no CTCs per
ml (data not shown). To further ensure that the cells labeled with
folate-AlexaFluor 488 were indeed malignant, the peripheral
blood samples from patients 1–5 were labeled with monoclonal
anti-human CA125 antibody plus the appropriate secondary
antibody conjugated to rhodamine-X. As shown in Fig. 2d, the
green fluorescence of folate-AlexaFluor 488 was only found on
cells labeled with rhodamine-X, demonstrating that the folate-
AlexaFluor-labeled cells indeed derive from ovarian cancer.
Table 2. Evaluation of the efficiency of labeling cultured cancer
cells added to whole human blood with folate conjugates
No. of cancer cells in 1
ml of blood
Efficiency of detection, %
Donor 1 Donor 2 Donor 3
10 100.0 100.0 100.0
102 100.0 100.0 100.0
103 100.0 99.2 100.0
104 99.8 99.8 99.6
105 99.8 99.6 99.7
Mean* 99.92  0.11 99.72  0.33 99.86  0.19
*The mean ( SD) represents the average labeling efficiency of folate conju-
gates in the whole blood from three different healthy donors.
Fig. 2. Quantitation of CTCs by both in vivo imaging of animal models and ex vivo flow cytometry of peripheral blood samples from ovarian cancer patients.
(a) Change in CTCs as a function of time after M109 tumor cell implantation. CTCs were quantitated by measuring the number of fluorescent tumor cells per
minute flowing through a blood vessel in the ear of each mouse. Red bars represent mean values. (b) Method of image processing. One thousand line scans,
spanning a 2-s time period, across a blood vessel are combined sequentially by using MATLAB software to yield the displayed image. (c) CTC counts in peripheral
blood samples from 12 ovarian cancer patients with different pathologies. Red bars represent mean values from multiple independent measurements. (d)
Confocal images of single CTC in blood smears from an ovarian cancer patient. Overlap of green (folate-AlexaFluor 488) with red (rhodamine-X-labeled
anti-cytokeratin antibody) fluorescence is displayed as yellow fluorescence. (Scale bar: 10 m.) (e) Comparison of the labeling intensities of folate-FITC (green)
and three different polyclonal anti-FR antibodies conjugated with FITC: PU9 (red), PU10 (yellow), and PU17 (navy). Unlabeled KB cells (black) and KB cells
incubated with 10 M folic acid plus 100 nM folate-FITC (orange, totally competed) serve as negative controls.
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Evaluation of Fluorescent Antibodies as Labeling Agents. Finally, as
mentioned above, antibody-based probes, including three distinct
polyclonal antibodies against FR, were also tested for their abilities
to identify rare CTCs in vivo. Curiously, no CTCs could be detected
in tumor-bearing mice after i.v. administration of any tumor-
specific antibody. This failure to detect CTCs by using antibodies
was not expected (data not shown), especially because the antibod-
ies were labeled with multiple copies of fluorescein (in contrast to
folate which was always linked to a single fluorescein or another
fluorescent molecule). To explain these data, we hypothesized that
our inability to detect CTCs might have arisen from either a failure
of the antibodies to bind CTCs in vivo or a rapid antibody-promoted
clearance of the opsonized CTCs by phagocytic cells (8). To explore
the former mechanism, we examined the capabilities of three
different FITC-conjugated anti-FR-specific polyclonal antibodies
to label FR KB cells in vitro. Although all three antibodies were
found to immunoblot FR in the KB cell extracts at 1:20,000
dilution, their abilities to stain KB cells in vitro was found to be
100-fold lower than folate-FITC (Fig. 2e). It is conceivable that
this difference in labeling efficiency might relate to the relative sizes
of folate-FITC (Mr  881) versus antibodies (Mr 160,000) and
their relative accessibilities to FR on the CTC surface. Whether
antibody labeling of the CTCs in vivo also contributed to their rapid
removal by the reticuloendothelial system was not investigated.
Discussion
The above data were all obtained by using folate as the targeting
ligand. Because not all cancers express FR, use of folate-dye
conjugates to detect recurrent disease in the clinic will necessarily
be limited to those patients whose primary tumors demonstrate FR
expression during initial immunohistochemical analysis of their
resected tumors. Detection of FR	 tumors must then depend on
development of analogous high-affinity ligands that are specific for
other cancers, as reported in the literature (24, 25).
Current in vivo diagnostic imaging technologies such as com-
puted tomography, MRI, and positron-emission tomography can
detect micrometastases only to a resolution of 2–3 mm (26). To
permit earlier detection of metastatic disease, an in vitro diagnostic
test, based on magnetic bead sorting followed by immunostaining
and fluorescence imaging, has been recently developed that can
detect 5 CTCs in 7.5 ml of human peripheral blood (1, 2).
Although this improvement in detection sensitivity will likely save
lives, its usefulness is limited by the volume of blood that can be
sampled, thereby compromising CTC detection during the initial
phases of metastasis, in early stages of disease, or when CTC
numbers are reduced by therapy. In contrast, intravital flow cy-
tometry circumvents sampling limitations and renders quantitation
of rare events (1 CTC per ml) statistically significant by enabling
analysis of the majority of a patient’s blood volume (5 liters).
Folate-dye conjugates were also found to enable quantitation of
CTCs in smaller blood volumes (2 ml) by conventional ex vivo flow
cytometry. Although ex vivo flow cytometry has the advantage that
detected cells (i) can be further characterized by forward and side
light scattering and (ii) can be sorted and subsequently studied by
other methods, it also suffers from the small sample size mentioned
above as well as the possible introduction of human errors during
sample preparation. Nevertheless, where CTC concentrations in
the blood are high, ex vivo flow cytometry should still constitute the
preferred method because of the common availability of the
necessary instrumentation. However, even for ex vivoCTC analyses,
data in Fig. 2e demonstrate that sensitivity can be greatly improved
(100-fold) by substitution of folate-dye conjugates for fluores-
cently labeled antibodies.
Despite the aforementioned advantages of intravital f low
cytometry, several challenges remain before the methodology
can be implemented in the clinic. First, because an average 70-kg
cancer patient will have 5 liters of blood, interrogation of the
patient’s entire blood volume will require at least1 h assuming
the blood vessel under observation has a diameter of 3 mm and
flows at a rate of 100 ml/min (27). Although it can be argued
that a patient’s entire blood volume need not be interrogated,
methods will still have to be developed to maintain the desired
blood vessel in focus for the desired duration of the assay.
Second, folate-dye conjugates must be shown to be completely
nontoxic before they can achieve routine use in the clinic.
Although folate-FITC (2.7 mmol/kg) is currently being admin-
istered i.v. to cancer patients with no discernable toxicity (folate-
hapten immunotherapy) (National Institutes of Health clinical
trial: Safety and Tolerability Study of FolateImmune in Com-
bination with Cytokines in Patients with Refractory or Meta-
static Cancer, clinical trial identifier: NCT00329368; see also ref.
28), none of the other folate-dye conjugates has been tested in
humans. However, because the concentration of folate-FITC
used to detect CTCs in tumor-bearing mice (Fig. 2a) is 10-fold
lower than that currently used in the above clinical trial, we
anticipate that folate-labeling agents will generally be well
tolerated. Third, consumption of high doses of folic acid could
conceivably raise serum folate concentrations to levels that
compete with folate-dye conjugates for binding to CTCs (29, 30).
Although no constraints were placed on vitamin utilization by
the cancer patients tested in Fig. 2c, it is conceivable that
abstinence from vitamin supplements for 24 h before CTC
analysis might have further improved the sensitivity of the assay.
Indeed, cancer patients to be scanned with a folate-linked 111In
radioimaging agent were asked to refrain from folic acid sup-
plements for 24 h before image collection (31). Such restrictions
could conceivably improve the signal-to-noise ratio seen in Fig.
1e. Finally, cancer patients have been frequently shown to have
measurable levels of anti-FR antibodies in their sera (32).
Although these antibodies could conceivably reduce folate-dye
conjugate binding to cancer cells, we have no data to suggest that
they compete with folate conjugates for FR. Rather, because
200 cancer patients have been successfully imaged with a
folate-linked radioimaging agent, we believe that interference
from anti-FR antibodies must be minimal, if present at all.
Although further optimization of the intravital flow cytometry
assay is warranted, the fact that CTC detection was successful with
multiple folate-dye conjugates (folate-rhodamine, folate-FITC, and
folate-AlexaFluor 488) on multiple cancer cells (KB, M109,
L1210A, and natural CTCs in ovarian cancer patients) suggests that
there is flexibility in the methodology if changes should be neces-
sary. Because better tools for the diagnosis and staging of cancer,
assessment of response to therapy, and evaluation of residual
disease after surgery can save lives, we suggest that optimization of
the methodology for human use is worth pursuing. Finally, it should
also be noted that high-affinity, low-molecular-weight ligands with
specificities for other rare populations of pathologic cells (e.g.,
bacteria, viruses, parasites, and activated immune cells) can be
similarly designed and synthesized for related applications.
Materials and Methods
Reagents. DiIC18 (3), Vybrant DiD cell-labeling solution, fluores-
cein isothiocyanate, anti-CA125 antibodies, and corresponding
secondary antibodies conjugated to rhodamine-X were purchased
from Invitrogen (Eugene, OR). Ficoll-Paque was purchased from
Amersham (Piscataway, NJ). Rabbit anti-FR antisera from three
separate rabbits, affinity columns, and folate-FITC were provided
by Endocyte, Inc (West Lafayette, IN).
Mice. All experimental protocols were approved by the Purdue
University Animal Care and Use Committee. For the identifi-
cation of the optimal imaging method, blood was collected from
anesthetized mice by paraorbital extraction in heparin. RBCs
were then isolated, labeled by DiI18 (3), and injected i.v. for the
optimization experiment as described below (33).
In vivo imaging experiments were carried out on 6- to 8-week-











old female BALB/c mice (Harlan Labs, San Diego, CA) fed a
folate-deficient chow for at least 2 weeks. Because commercial
chow is supplemented with very high levels of folic acid, mice fed
on this chow have serum folate concentrations near 700 nM (34,
35), a value 50 times greater than normal. We have found that
2–3 weeks of exposure to folate-deficient chow is sufficient to
lower murine serum folates to a level (20 nM) comparable to
that of human serum (29, 34–36). When desired, anesthesia was
performed by i.p. injection of Avertin (500 mg/kg). Each anes-
thetized animal was placed in a chamber with its ear taped to the
bottom of the dish by using double-faced tape.
L1210A and M109 cells were cultured in folate-deficient RPMI
1640 (Gibco, Rockville, MD) for several weeks to up-regulate FR
expression to levels commonly found in ovarian cancers (3 106
FR per cell) (17). At the time of tumor implantation, L1210A and
M109 cells expressed 3.5  106 and 1  106 FR per cell,
respectively. For the L1210A tumor model, 106 L1210A cells were
injected through one of the lateral tail veins, and 20 min later, 5
nmol per mouse of folate-rhodamine was injected through the other
tail vein. For specificity studies, L1210A cells were labeled ex vivo
with DiD before tail vein injection. Mice were then treated i.v. with
5 nmol of folate-FITC and imaged as stated above. For the M109
metastatic cancer model, 5  105 passage 0 or 1 (P0 or P1) M109
cells isolated from a s.c. tumor were implanted s.c. on the back of
the mouse. Folate-rhodamine (5 nmol per mouse) was injected
through the tail vein for in vivo labeling. Microscopic necropsy,
H&E pathological examination, and immunohistochemistry were
carried out by veterinary pathologists at the Animal Disease
Diagnostic Laboratory of Purdue University to identify metastatic
sites in different organs.
Flow Cytometry. To evaluate the labeling efficiency of folate
conjugates in human whole blood, fresh blood was obtained from
three healthy donors in heparinized tubes and spiked with
different numbers (10–105/ml) of DiD-labeled KB cells (a
human nasopharyngeal cell line). The blood samples were then
incubated with 100 nM folate-AlexaFluor 488 for 30 min at 37°C
before analysis by flow cytometry. Efficiency of detection was
calculated by dividing the number of folate-AlexaFluor 488-
positive cells by the number of DiD-positive cells.
To quantitate CTC levels in blood samples from patients
with ovarian cancer, whole blood samples in anticoagulant
were obtained under the auspices of an Institutional Review
Board-approved protocol at the Mayo Clinic. Each patient’s
sample was separated into four 500-l aliquots, three of which
were incubated with 100 nM folate-AlexaFluor 488 at 37°C for
30 min, and the fourth was first incubated with 10 M folic acid
for 30 min at 37°C before the above incubation with 100 nM
folate-AlexaFluor 488. This fourth sample served as a non-
specific binding control. FR cells were then counted by using
appropriate gates and controls by f low cytometry.
For comparison of the labeling efficiencies of folate-FITC
with three FITC-labeled anti-FR antibodies, cultured KB cells
were incubated for 30 min at 37°C with each of the above
probes before analysis by f low cytometry. Unlabeled KB cells
and KB cells incubated with 10 M unconjugated folic acid
before addition of 100 nM folate-FITC (totally competed)
served as negative controls.
Immunocytochemistry. The patient blood samples were treated with
folate conjugates as stated above. After labeling, CTCs were
enriched by Ficoll-Paque density centrifugation separation and
labeled with primary anti-CA125 antibodies and appropriate sec-
ondary antibodies conjugated with rhodamine-X. The treated
samples were then washed and examined by confocal fluorescence
microscopy.
Folate Conjugates and Antibody Conjugates. Folate conjugates
were synthesized as reported in the literature (37, 38). Anti-FR
polyclonal antibodies, PU9, PU10, and PU17, were purified by
affinity column chromatography and transferred to PBS (pH
9.0) for conjugation. Fluorescent labeling was carried out at a
ratio of 80 g of FITC per milligram of antibody at room
temperature for 4 h in the dark. After conjugation, labeled
antibodies were purified by affinity chromatography and trans-
ferred to PBS (pH 7.4). Antibody concentration and FITC-
to-protein ratio were calculated by using the following for-
mula, which is based on IgG and FITC absorbance values:
concentration (mg/ml)  [A (280) 	 0.31  A (495)]/1.4,
FITC-to-protein ratio  3.1  A (495)/[A (280) 	 0.31  A
(495)].
In Vivo Imaging. In vivo imaging of DiIC18 (3)-labeled RBCs was
conducted on a laser-scanning microscope (IX70/FV300;
Olympus, Tokyo, Japan) that was modified to permit rapid
interconversion between nonconfocal, confocal, and two-
photon excitation f luorescence (TPEF) imaging. A 543-nm
He-Ne laser was used for one-photon excitation, whereas a
femtosecond Ti:Sapphire laser (Mira900; Coherent, Santa
Clara, CA) was used for two-photon excitation. The Ti:Sap-
phire laser had a 78-MHz repetition rate and 200-fs pulse
duration. A 40 IR water-immersion objective (1-UM568;
Olympus) with a working distance of 3.3 mm and numerical
aperture of 0.8 was used to focus the laser onto a vessel in the
mouse ear. Fluorescence was collected through the same
objective and filtered with either a HQ520 nm/40 nm bandpass
filter (Chroma, Brattleboro, VT) for FITC detection or a 600
nm/65 nm filter (Ealing Catalog, Rocklin, CA) for rhodamine
detection. For imaging L1210A cells labeled with both folate-
FITC and DiD (a 670 nm/40 nm filter was used when DiD was
imaged), the same laser was tuned to 790 nm. The epif luo-
rescence was measured with photomultiplier tube (PMT)
detectors (R3896; Hamamatsu, Bridgewater, NJ). For imaging
folate-rhodamine, the Ti:Sapphire laser was tuned to 730 nm
with 80-mW output at the objective lens. To further improve
the signal-to-background ratio, an external PMT (H7422–40;
Hamamatsu) was used for in vivo imaging of CTCs.
Image Processing. DiIC18 (3)-labeled RBCs were injected into
the tail veins of BALB/c mice and imaged in vivo by time-lapse
microscopy by using each of the indicated methods. The signal
and background f luorescence intensities and signal-to-
background (S/B) ratios were quantified on single cells by
using FlowView software (Olympus; version 4.3) as they
passed under the scanner. Statistics (average and standard
deviation) were derived from six time series images spanning
1 min for each imaging technique. All comparisons of non-
confocal (n  744), confocal (n  600), and multiphoton (n 
329) microscopy were performed on the same blood vessel
by changing the optical setup while the mouse remained
anesthetized.
For analysis of folate-rhodamine blood clearance kinetics,
two-dimensional scans were recorded every 5 s. Blood vessel
f luorescence intensities were quantified in each image by
calculating the mean f luorescence by using the FlowView
software (Olympus; version 4.3). For quantitation of CTCs,
digitized signals collected during one-dimensional line scan-
ning were exported and then analyzed by programming on
MATLAB 7.0 platform. High-frequency noise was eliminated
with a fast Gaussian filter, and the processed digitized data
were imported into Origin 7.0 for visual presentation of
f luorescent cells.
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